Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial
Authors Lipton RB, Munjal S, Dodick DW, Tepper SJ, Serrano D, Iaconangelo C
Received 19 October 2020
Accepted for publication 16 January 2021
Published 25 February 2021 Volume 2021:14 Pages 549—560
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Robert B. Raffa
Richard B Lipton,1 Sagar Munjal,2 David W Dodick,3 Stewart J Tepper,4 Daniel Serrano,5 Charlie Iaconangelo5
1Neurology, Epidemiology and Population Health, and Psychologyand Behavioral Sciences Departments, Albert Einstein College of Medicine, Bronx, NY, USA; 2Clinical Development, Operations, and Medical Affairs, Dr. Reddy’s Laboratories, Princeton, NJ, USA; 3Neurology Department, Mayo Clinic, Scottsdale, AZ, USA; 4Neurology Department, Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 5Biostatistics Department, Pharmerit Inc., Bethesda, MD, USA
Correspondence: Sagar Munjal
Dr. Reddy’s Laboratories, 107 College Road East, Princeton, NJ, 8540, USA
Tel +1 609-375 9900
Email [email protected]
Background: Nonsteroidal anti-inflammatory drugs are widely used for migraine, but gastrointestinal tolerability limits use. We previously reported results from the first treatment period of this 2-period, randomized, controlled study comparing DFN-15—an oral, ready-made liquid solution of a selective cyclo-oxygenase-2 inhibitor celecoxib—with placebo for the acute treatment of a moderate-severe migraine attack. Herein, we report the effects of treatment for the second treatment period.
Methods: In the first treatment period of this trial, adults with migraine were randomized to double-blind trial treatment of attacks of moderate or severe pain with DFN-15,120 mg or placebo. For the second treatment period, reported herein, participants were re-randomized to treat an attack of any baseline pain intensity (mild, moderate, or severe). Co-primary efficacy endpoints specified for the first attack were not specified for the second attack.
Results: Of the 531 patients who completed the first treatment period, 491 (n = 243 DFN-15; n = 248 placebo; 87% female, mean age 41 years) were re-randomized into the second double-blind treatment period. Baseline pain intensity was mild in 17.2% (85/493) of patients, moderate in 58.4% (288/493) of patients, and severe in 22.9% (113/493) of patients. At 2 hours post-dose, DFN-15 was superior to placebo for freedom from pain (46.2% [110/238] vs 31.1% [76/244], p ≤ 0.001) and the most bothersome symptom (63.4% [121/191] vs 50.0% [98/196], p = 0.010). Treatment-emergent adverse events (TEAEs) occurred in 7.1% (35/493) of patients (DFN-15: 6.1% [15/244]; placebo 8.0% [20/249]). Study drug-related TEAEs occurred in 5.1% (25/493) of patients (DFN-15: 4.5% [11/244]; placebo 5.6% [14/249]); nausea (1% [5/493]) and dysgeusia (0.8% [4/493]) were most common. No serious TEAEs, severe TEAEs, or TEAEs leading to study drug termination were reported.
Conclusions: DFN-15 was superior to placebo for pain freedom and freedom from the most bothersome symptom when patients treat a migraine attack of any baseline pain intensity. Rates of TEAEs did not differ between treatment groups.
Keywords: migraine, acute treatment, celecoxib, oral liquid
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]